Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Investigational Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer

NCT04575961 is registered in ClinicalTrials.gov with North Eastern German Society of Gynaecological Oncology as lead sponsor.

NCT NCT04575961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04575961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Investigational Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
Lead sponsor
North Eastern German Society of Gynaecological Oncology
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 22, 2022
Completion date
March 1, 2028
Enrollment
33 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, low grade serous carcinoma, ovarian cancer, primary peritoneal carcinoma